ITOMIC Publishes First Results from Pan-Omic Triple-Negative Breast Cancer Trial

ITOMIC Publishes First Results from Pan-Omic Triple-Negative Breast Cancer Trial

TNBCs are a subset of breast cancers that lack the conventional markers of breast cancer — HER2, estrogen receptor, and progesterone receptor — making the cancer that much harder to treat since those markers are targets for most chemotherapies.

(Visited 3 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.